ETIDIOH - NEW

  {Excerpt} Avian Influenza Report - Reporting period: February 1, 2026 – February 7, 2026 (Week 6) (Published on February 10, 2026)   -- Avian influenza A(H9N2) :  1) Guangdong Province :  - A 73-year-old woman with onset on January 17, 2026.  2) Hunan Province :  - A 2-year-old boy with onset on December 29, 2025.  -- Avian influenza A(H10N3) : 1) Guangdong Province :  - A 34-year-old man with onset on December 29, 2025.   (...) Source:  Link:  https://www.chp.gov.hk/files/pdf/2026_avian_influenza_report_vol22_wk06.pdf ____

  {Summary} In summer 2025, the SARS-CoV-2 JN.1 sublineage became dominant with more resistant variants, such as XFG, LP.8.1, and NB.1.8.1 . COVID-19 mRNA boosters were therefore updated for the 2025–2026 season to target the LP.8.1 spike .1 Previous boosters, particularly the WA1/2020+BA.5 bivalent booster , were characterised by substantial boosting of the ancestral strain , a phenomenon known as immune imprinting .2,3 We therefore evaluated whether the phylogenetically more distant LP.8.1 mRNA booster would preferentially boost currently circulating strains. Recent data from European and Asian populations have reported the immunogenicity of the LP.8.1 mRNA booster .4,5 Herein, we report the immunogenicity of the LP.8.1 mRNA booster in a US population with a different exposure history and high population immunity. We show that the LP.8.1 mRNA booster induced neutralising antibody (NAb) and binding antibody responses, primarily to the vaccine-matched L.P.8.1 variant and other curr...

  Abstract We examined 89 travel-related clade Ib monkeypox virus cases detected in 33 countries during August 2024–July 2025 . Most cases were among men ; about one third led to secondary transmission . Secondary transmission risk was highest among sexual, then household, contacts. Those groups should be the focus of response strategies and interventions. Source:  Link:  https://wwwnc.cdc.gov/eid/article/32/2/25-1530_article ____

  Significance Middle East respiratory syndrome coronavirus (MERS-CoV) remains the most lethal human coronavirus , with continued zoonotic transmission from wild naturally infected dromedary camels , posing a persistent risk of spillover to humans. Despite this ongoing threat , no specific antiviral treatment has been approved. In this study, we characterize the antibody response to MERS-CoV in naturally infected dromedaries, the primary animal reservoir, and identify a panel of nanobodies (Nbs) exhibiting potent neutralizing activity . These Nbs recognize a previously unreported binding and neutralizing site on the virus spike receptor-binding domain (RBD). Their distinctive genetic, structural, and functional properties make them promising candidates for the development of effective and therapeutic interventions against MERS-CoV, as strongly advocated by global health authorities. Abstract Wild dromedary camels in the Arabian Peninsula and Africa have harbored antibodies against ...